Clinical trials: Alzheimer's Disease Prevention
Alzheimer Disease
Multiregional rtfMRI Neurofeedback for the Prevention of Alzheimer's Disease (NPAD)
This study aims to predict cognitive decline using a performance endophenotype of neuro-feedback based on functional magnetic resonance imaging in real time in a population at risk for Alzheimer's disease (AD).
- Trial name
- NPAD (NCT03173846)
- Where
- Spain
- Volunteers
- 90 people
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Cognitive Decline, Alzheimer Disease
Effects of Real vs. Soundless Acoustic Stimulation During Deep Sleep on Brain Activity, Memory, and Blood Biomarkers in Older Adults (60-85) With Mild Memory Impairment
This study aims to explore a non-invasive way to improve memory and slow cognitive decline in older adults by enhancing sleep quality.
- Conditions
- Cognitive Decline, Alzheimer Disease, Subjective Cognitive Decline (SCD), Mild Cognitive Impairment (MCI)
- Trial name
- NCT06669546
- Testing
- Phase-locked auditory stimulation (PLAS)
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- University of Bern
Alzheimer Disease, Dementia
Reducing Dementia Risk With Digital Health Coaching
The Digital Cognitive Multi-domain Alzheimer's Risk Velocity (DC MARVEL) study is a 2-year randomized controlled trial on dementia prevention.
- Conditions
- Alzheimer Disease, Dementia, Mild Cognitive Impairment, Cognitive Decline
- Trial name
- DC-MARVEL (NCT04559789)
- Testing
- MindMate + Health Coaching, Health Education
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Neurotrack Technologies, Inc.
Alzheimers Disease
A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease
The purpose of this study is to determine the effects of CNP520 on cognition, global clinical status, and underlying AD pathology, as well as the safety of CNP520, in people at risk for the onset of clinical symptoms of AD based…
- Trial name
- GS2 (NCT03131453)
- Testing
- CNP520 50mg, CNP520 15mg
- Where
- 194 sites in United States, Argentina and 23 more
- Volunteers
- 1,145 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Alzheimer's Disease, Dementia
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
This is an open label study to treat dominantly inherited Alzheimer's disease (DIAD) mutation carrier participants from the DIAN-TU-001 gantenerumab Open Label Extension (OLE) period with lecanemab to determine the effects of…
- Conditions
- Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
- Trial name
- DIAN-TU (NCT06384573)
- Testing
- lecanemab
- Where
- 6 sites in United States, Australia and 1 more
- Volunteers
- 40 people
- Sponsor
- Washington University School of Medicine
Psychosis Associated With Alzheimer's Disease
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease.
- Trial name
- NCT05511363
- Testing
- KarXT
- Where
- 129 sites in United States, Bulgaria and 11 more
- Volunteers
- 410 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Down Syndrome, Alzheimer Disease
Trial-Ready Cohort-Down Syndrome (TRC-DS)
The purpose of the Trial-Ready Cohort - Down Syndrome (TRC-DS) is to enroll 120 healthy adults with Down syndrome (DS), between the ages of 25-55, into a trial ready cohort (TRC), and up to 550 participants in total including…
- Conditions
- Down Syndrome, Alzheimer Disease, Dementia
- Trial name
- TRC-DS (NCT04165109)
- Where
- 22 sites in United States, France and 3 more
- Volunteers
- 550 people
- Sponsor
- University of Southern California
Alzheimer's Disease
Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants
Study to understand factors related with the preclinical stages of Alzheimer's Disease and investigate markers that predict its progression.
- Trial name
- NCT02685969
- Testing
- 18F-Flutemetamol & 18F-FDG
- Where
- Spain
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Delirium, Dementia
The Prevention Program for Alzheimer's Related Delirium (PREPARED) Trial
By the year 2038, over a million Canadians are expected to have Alzheimer's disease, a type of dementia. Dementia increases the risk of nursing home placement among the elderly more than fivefold.
- Trial name
- PREPARED (NCT03718156)
- Testing
- PREPARED Trial Intervention
- Where
- 6 sites in Canada
- Volunteers
- 800 people
- Sponsor
- McGill University
Alzheimers Disease, Dementia
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU-002 (NCT06647498)
- Testing
- Remternetug
- Where
- 37 sites in United States, Argentina and 13 more
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Aging
Lifestyle for the BRAin Health - Time Restricted Eating and Mindfulness
The study aims to evaluate the effects of a 9-month intervention combining yoga-based mindfulness techniques, cognitive training, and nutritional counseling on cognitive function, plasma markers of neurodegeneration (tau…
- Conditions
- Alzheimer Disease, Aging, Lifestyle Factors, Cognitive Impairment
- Trial name
- LIBRA REMIND (NCT07042087)
- Testing
- Mindfulness Yoga, Time-Restricted Eating with nutritional counseling promoting a flexitarian dietary pattern, Cognitive Training
- Where
- Czechia
- Volunteers
- 48 people
- Sponsor
- St. Anne's University Hospital Brno, Czech Republic
Postpartum Depression, Postpartum Anxiety
Feasibility & Acceptability of App-based Cognitive Behavioral Therapy for Postpartum Depression Prevention
Postpartum depression (PPD) affects up 10-15% of mothers overall, but the rate of PPD can be as high as 25% among mothers with personal or obstetric risk factors.
- Conditions
- Postpartum Depression, Postpartum Anxiety, Stress
- Trial name
- NCT06365645
- Testing
- M.Bapp, App-based parenting education
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Women and Infants Hospital of Rhode Island
Alzheimer Disease
HAPPCAP-AD (Human-APPlication Combined Approach for Prevention of Alzheimer's Disease)
Currently, Alzheimer's disease (AD) has no cure putting prevention-strategies in the forefront for impeding the public health and personal consequences of this devastating disease.
- Trial name
- HAPPCAP-AD (NCT05256121)
- Testing
- AD Risk factors balance
- Where
- Israel
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Dementia of the Alzheimer Type
Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI
The study aims to detect the effect of a structured cognitive rehabilitation program, teh stage specific intervention STACog, on cognitive performance and functional activation in fMRI in a group of patients with mild cognitive…
- Trial name
- ECIF (NCT01329601)
- Testing
- StaCog, stage specific cognitive Intervention, booklet based training
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- University of Rostock
Cognitive Dysfunction, Alzheimer Disease
ALA-enriched Nutrition for Prevention of Cognitive Decline in APOE4 Older Adults
This randomized, double-blind, placebo-controlled pilot trial will evaluate the effects of alpha-linolenic acid (ALA) supplementation on cognitive function, blood-brain barrier integrity, and brain vascular health in older adults…
- Conditions
- Cognitive Dysfunction, Alzheimer Disease, Blood-Brain Barrier, Apolipoprotein E, Deficiency or Defect of
- Trial name
- NCT07392723
- Testing
- Alpha-Linolenic Acid (2.6 g/day)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Michal Schnaider Beeri, Ph.D.
Intellectual Disability, Neurodevelopmental Disorders
Physical Activity and Community EmPOWERment Project
Purpose: Conduct a wait-list randomized controlled trial (RCT) of an inclusive physical activity program called PACE for adults with intellectual disability (ID) who are not yet showing signs of Alzheimer's Disease…
- Conditions
- Intellectual Disability, Neurodevelopmental Disorders, Autism Spectrum Disorder, Down Syndrome
- Trial name
- PACE (NCT06740162)
- Testing
- PACE Program
- Where
- 2 sites in United States
- Volunteers
- 376 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Alzheimer's Disease
Pilot Study of Aerobic Exercise in Early Alzheimer's Disease(AD)
The current project is a natural extension of a programmatic line of investigation into the relationship between exercise, brain aging, and AD that Dr. Burns has developed over the last four years.
- Trial name
- NCT01128361
- Testing
- Aerobic Exercise, Stretching
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Jeff Burns, MD
Low Education, Cognition
MINDSpeed Food and Brain Training RCT
The purpose of this study is to learn how foods high in polyphenols and brain training exercises affect older adults' cognitive performance
- Conditions
- Low Education, Cognition, Cognitive Training, Polyphenols
- Trial name
- MINDSpeed (NCT03419052)
- Testing
- Speed of processing training, MIND foods, Cognitive training control
- Where
- United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- Indiana University
Alzheimer Disease, Dementia
Follow-up Study of the Alzheimer's Disease Anti-Inflammatory Prevention Trial
The Alzheimer's Disease Anti-inflammatory Prevention Trial - Follow-up Study (ADAPT-FS) will continue observations of the declared primary outcomes of the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) in the…
- Trial name
- ADAPT-FS (NCT01417130)
- Where
- 6 sites in United States
- Volunteers
- 1,650 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
At Risk for AD-dementia, With Subjective Cognitive Decline, At Risk for Cognitive Decline
High-Velocity Resistance Training for Brain Blood Flow and Cognitive Function in Older Adults
The goal of this clinical trial is to learn whether a 12-week high-velocity resistance training program can improve brain blood flow and thinking skills in adults ages 60 to 79 who are at higher risk for Alzheimer's disease and…
- Trial name
- NCT07444554
- Testing
- High-Velocity Resistance Training
- Volunteers
- 60 people
- Sponsor
- University of Illinois Chicago